TEVA

Teva Pharmaceutical Industries Ltd. ADR (TEVA) | Rumor.io

Teva Pharmaceutical Industries

TEVA

Attention (50-day avg)0.02%

Attention rank (50-day avg)#305

Bullish sentiment (50-day avg)96%

Price to earnings ratio64.9

Market capitalization45.3B

Earnings per share0.6

Dividend yield (TTM)0.87%

Revenue (annual)17.3B

Net income (annual)1.4B

Social

What share of all stock conversation is about TEVA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0.03% +0.02	0% -0.01

Sep 2

TEVA's Anti-IL-15 antibody has shown positive results in a Phase 2a study for Celiac Disease, meeting the primary endpoint and limiting gluten-induced intestinal damage.
The study's positive results further validate TEVA's pipeline-in-a-product potential, which could lead to significant growth for the company.
TEVA's stock has experienced significant movement, with some analysts predicting the company could become a $100 billion company if it can successfully develop treatments for gastrointestinal problems.

Generated by AI

Sentiment

Of the messages about TEVA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +37.5	94.55% +2.88	88.43% +24.54
Bearish	—	0% -37.5	5.45% -2.88	11.57% -24.54

Bullish· Apr 29

Teva Pharmaceutical Industries Limited has successfully transformed its business structure, with its innovative drug sales surging 41% and indicating a strong growth strategy.
The company's Q1 earnings beat expectations, with adjusted EPS of $0.53 and revenue of $3.982B, representing a 1.92% and 2.34% year-over-year increase, respectively.
Teva's acquisition of Emalex Biosciences adds a first-in-class therapy to its neuroscience pipeline, expanding its innovative medicines and supporting both near- and long-term growth.

Bearish· May 7

$TEVA is showing unusual price action, potentially indicating a reversal in the near future.
The company's recent decision to offshoring jobs may have missed expectations and negatively impacted revenue.
The CEO's statement that Teva may hike generic drug prices if Trump imposes tariffs could lead to a significant market event and potentially crater the stock.

Generated by AI

Topics

Of the messages about TEVA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	25%	0.4%	14.17%
Technical Analysis	—	0%	0.3%	6.87%
Analysts	—	75%	0.71%	2.87%
Macro	—	0%	98.58%	73.52%
Earnings	—	0%	0.01%	2.4%
Controversies	—	0%	0%	0.17%

Earnings· Nov 5

Teva Pharmaceutical Industries' Q3 2025 earnings beat expectations with 33% growth in branded drugs, led by Austedo, and a 12% stock surge.
The company reported non-GAAP EPS of $0.78, beating estimates by $0.11, and revenue of $4.48B, beating estimates by $150M.
Teva raised its FY25 guidance for non-GAAP EPS to $2.55-$2.65 and narrowed its sales guidance to $16.8B-$17.0B, driven by strong sales of its innovative drug portfolio.

Analysts· Feb 12

Piper Sandler upgraded Teva Pharmaceutical Industries Limited ($TEVA) to Overweight from Neutral, with a new price target of $19.
The upgrade is based on multiple expansion, with shares up 3.25% in early trade.
The price target increase from $12 to $19 represents a potential upside of 58.2%.

Announcements· Apr 29

Teva Pharmaceutical Industries Limited is acquiring Emalex Biosciences for $700 million upfront, plus up to $200 million in milestones, to add ecopipam, a near-approval Tourette syndrome drug, to its neuroscience pipeline.
The acquisition is expected to accelerate Teva's pivot to growth strategy and expand its innovative medicines pipeline in the neuroscience area.
Teva's Q1 2026 earnings report showed a 2.3% year-over-year revenue growth to $3.98 billion, beating the FactSet consensus, with the company reaffirming its FY26 revenue guidance of $16.40-16.80 billion.

Controversies· Aug 21

Teva Pharmaceutical Industries Limited (TEVA) has agreed to pay $225M in criminal fines to resolve charges related to price fixing.
The company will pay a $225M fine over five years, with $22.5M due each year from 2024 to 2027 and $135M due in 2028.
Teva has also agreed to divest a generic drug as part of the settlement, which includes allegations that a former employee conspired with competitors to fix prices.

Macro· Apr 20

Tariffs on pharmaceutical imports could impact US API manufacturing stocks, including Pfizer, Merck, and Teva, which have both domestic and global manufacturing locations.
Perrigo, an OTC API provider, has US-based manufacturing locations and could benefit if tariffs drive more production within the US.
A deep dive on each company's manufacturing operations and bottom-line impact is needed to determine the effect of pharmaceutical tariffs.

Technical Analysis· Dec 17

Teva Pharmaceutical Industries Limited (TEVA) has shown a strong price increase, going from $16.50 to $18.80, and then to a new 6-year high at $19.48.
The stock has formed a defined channel and has been trading in a stable range, with potential support levels at $18 and $17.50.
Technical analysts believe that TEVA has the potential to continue moving upwards, with potential targets at $19.75 and possibly $21, but with a risk of falling to $19 or $18 if it stays below $21.60.

Generated by AI

Community

Of the messages about TEVA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	57.14%	1.98%	33.97%
Newcomers	—	42.86%	98.02%	66.03%

Regulars· Jul 29

Teva Pharmaceutical Industries Limited's Q2 earnings report showed a significant decline in GAAP EPS, but the company exceeded revenue guidance expectations and provided a bullish forward guidance for 2026 revenue and non-GAAP operating income.
The company's Austedo medication continues to lead its branded commercial pack, with sales growing 40% in the second quarter to $696 million at local currencies.
Teva's innovation engine has offset the slump in generics, and the company's non-GAAP diluted EPS guidance for 2026 is expected to be between $1.91 and $2.11.

Newcomers· Jan 29

Newcomers are drawn to Teva Pharmaceutical Industries Limited, with some discussing its news and fundamentals, while others are focused on its potential for growth and a wide upside path.
The company's growing revenue and valuation are seen as setting up a favorable situation, with a target zone of $1.34–$1.36.
There is a growing interest in Teva's news and developments, with multiple articles and explanations being shared and discussed among newcomers.

Generated by AI

News

Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround

Built on substance, not hype, Teva's mega rally is just getting started.

1d agofinance.yahoo.com

Teva Enters Acceleration Phase of Transformation Supported by Multi-Year Launch Cycle, Oppenheimer Says

Teva Pharmaceutical (TEVA) is entering a strong growth phase despite near-term concerns around Auste

6d agoYahoo Finance

Viatris, Teva initiated at Outperform at Oppenheimer

6d agoseekingalpha.com

Teva Eyes New Growth Phase After Securing Investment-Grade Ratings

Teva Pharmaceutical Industries (NYSE:TEVA) is planning for greater financial flexibility after receiving investment-grade ratings from all three major credit rating agencies, President and CEO Richard Francis said at the BofA Global Healthcare Conference. Francis said the company achieved the miles

7d agoYahoo Finance

Oppenheimer initiates Teva stock with outperform rating on pipeline

7d agoInvesting.com

Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline

Teva Pharmaceutical Industries (NYSE:TEVA) Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a generics manufacturer toward a biopharmaceutical company with a growing innovative medicines portfolio, while maintaining and expanding its generics operat

8d agoYahoo Finance

Also Discussed

Investors talking about TEVA also mention

#	Name	Attention
1	Perrigo Company plcPRGO	0%0
2	Novartis AG Sponsored ADRNVS	0%-0.01
3	Johnson & JohnsonJNJ	0%-0.06
4	Amneal Pharmaceuticals, Inc.AMRX	0%+0
5	Amgen Inc.AMGN	0.01%+0
6	Sanofi ADRSNY	0%-0.01
7	Bristol-Myers Squibb CompanyBMY	0.01%0
8	GSK plc ADRGSK	0%0
9	TARO - Taro Pharmaceutical Industries Ltd.	——
10	Biogen IncBIIB	0%-0.01

Teva Pharmaceutical Industries Ltd. ADR

Healthcare
Drug Manufacturers - Specialty & Generic

Teva Pharmaceutical Industries Ltd. ADR represents shares of an Israeli-based global pharmaceutical company focused on developing, manufacturing, and marketing medicines across multiple therapeutic areas. Teva is widely recognized for its large portfolio of generic drugs, which provide cost-effective alternatives to branded treatments and support healthcare systems in controlling medication expenditure. Alongside generics, Teva offers specialty and biopharmaceutical products in fields such as central nervous system disorders, respiratory conditions, oncology, and other chronic diseases. The company serves hospitals, pharmacies, healthcare providers, and wholesalers across North America, Europe, and a broad range of international markets through regionally organized business segments. Teva also engages in the sale of active pharmaceutical ingredients and provides contract manufacturing services, reinforcing its role in the wider pharmaceutical supply chain. Founded in 1901 and headquartered in Tel Aviv, Israel, Teva Pharmaceutical Industries Ltd. ADR gives investors exposure to one of the world’s leading players in generic and branded pharmaceutical products.

Website

Location

124 Dvora HaNevi’a St.

Tel Aviv-Yafo, 6944020

Israel

Social

What share of all stock conversation is about TEVA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0.03% +0.02	0% -0.01

Sep 2

TEVA's Anti-IL-15 antibody has shown positive results in a Phase 2a study for Celiac Disease, meeting the primary endpoint and limiting gluten-induced intestinal damage.
The study's positive results further validate TEVA's pipeline-in-a-product potential, which could lead to significant growth for the company.
TEVA's stock has experienced significant movement, with some analysts predicting the company could become a $100 billion company if it can successfully develop treatments for gastrointestinal problems.

Generated by AI

Sentiment

Of the messages about TEVA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +37.5	94.55% +2.88	88.43% +24.54
Bearish	—	0% -37.5	5.45% -2.88	11.57% -24.54

Bullish· Apr 29

Teva Pharmaceutical Industries Limited has successfully transformed its business structure, with its innovative drug sales surging 41% and indicating a strong growth strategy.
The company's Q1 earnings beat expectations, with adjusted EPS of $0.53 and revenue of $3.982B, representing a 1.92% and 2.34% year-over-year increase, respectively.
Teva's acquisition of Emalex Biosciences adds a first-in-class therapy to its neuroscience pipeline, expanding its innovative medicines and supporting both near- and long-term growth.

Bearish· May 7

$TEVA is showing unusual price action, potentially indicating a reversal in the near future.
The company's recent decision to offshoring jobs may have missed expectations and negatively impacted revenue.
The CEO's statement that Teva may hike generic drug prices if Trump imposes tariffs could lead to a significant market event and potentially crater the stock.

Generated by AI

Topics

Of the messages about TEVA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	25%	0.4%	14.17%
Technical Analysis	—	0%	0.3%	6.87%
Analysts	—	75%	0.71%	2.87%
Macro	—	0%	98.58%	73.52%
Earnings	—	0%	0.01%	2.4%
Controversies	—	0%	0%	0.17%

Earnings· Nov 5

Teva Pharmaceutical Industries' Q3 2025 earnings beat expectations with 33% growth in branded drugs, led by Austedo, and a 12% stock surge.
The company reported non-GAAP EPS of $0.78, beating estimates by $0.11, and revenue of $4.48B, beating estimates by $150M.
Teva raised its FY25 guidance for non-GAAP EPS to $2.55-$2.65 and narrowed its sales guidance to $16.8B-$17.0B, driven by strong sales of its innovative drug portfolio.

Analysts· Feb 12

Piper Sandler upgraded Teva Pharmaceutical Industries Limited ($TEVA) to Overweight from Neutral, with a new price target of $19.
The upgrade is based on multiple expansion, with shares up 3.25% in early trade.
The price target increase from $12 to $19 represents a potential upside of 58.2%.

Announcements· Apr 29

Teva Pharmaceutical Industries Limited is acquiring Emalex Biosciences for $700 million upfront, plus up to $200 million in milestones, to add ecopipam, a near-approval Tourette syndrome drug, to its neuroscience pipeline.
The acquisition is expected to accelerate Teva's pivot to growth strategy and expand its innovative medicines pipeline in the neuroscience area.
Teva's Q1 2026 earnings report showed a 2.3% year-over-year revenue growth to $3.98 billion, beating the FactSet consensus, with the company reaffirming its FY26 revenue guidance of $16.40-16.80 billion.

Controversies· Aug 21

Teva Pharmaceutical Industries Limited (TEVA) has agreed to pay $225M in criminal fines to resolve charges related to price fixing.
The company will pay a $225M fine over five years, with $22.5M due each year from 2024 to 2027 and $135M due in 2028.
Teva has also agreed to divest a generic drug as part of the settlement, which includes allegations that a former employee conspired with competitors to fix prices.

Macro· Apr 20

Tariffs on pharmaceutical imports could impact US API manufacturing stocks, including Pfizer, Merck, and Teva, which have both domestic and global manufacturing locations.
Perrigo, an OTC API provider, has US-based manufacturing locations and could benefit if tariffs drive more production within the US.
A deep dive on each company's manufacturing operations and bottom-line impact is needed to determine the effect of pharmaceutical tariffs.

Technical Analysis· Dec 17

Teva Pharmaceutical Industries Limited (TEVA) has shown a strong price increase, going from $16.50 to $18.80, and then to a new 6-year high at $19.48.
The stock has formed a defined channel and has been trading in a stable range, with potential support levels at $18 and $17.50.
Technical analysts believe that TEVA has the potential to continue moving upwards, with potential targets at $19.75 and possibly $21, but with a risk of falling to $19 or $18 if it stays below $21.60.

Generated by AI

Community

Of the messages about TEVA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	57.14%	1.98%	33.97%
Newcomers	—	42.86%	98.02%	66.03%

Regulars· Jul 29

Teva Pharmaceutical Industries Limited's Q2 earnings report showed a significant decline in GAAP EPS, but the company exceeded revenue guidance expectations and provided a bullish forward guidance for 2026 revenue and non-GAAP operating income.
The company's Austedo medication continues to lead its branded commercial pack, with sales growing 40% in the second quarter to $696 million at local currencies.
Teva's innovation engine has offset the slump in generics, and the company's non-GAAP diluted EPS guidance for 2026 is expected to be between $1.91 and $2.11.

Newcomers· Jan 29

Newcomers are drawn to Teva Pharmaceutical Industries Limited, with some discussing its news and fundamentals, while others are focused on its potential for growth and a wide upside path.
The company's growing revenue and valuation are seen as setting up a favorable situation, with a target zone of $1.34–$1.36.
There is a growing interest in Teva's news and developments, with multiple articles and explanations being shared and discussed among newcomers.

Generated by AI

Teva Pharmaceutical Industries

Social

Sep 2

Bullish· Apr 29

Bearish· May 7

Earnings· Nov 5

Analysts· Feb 12

Announcements· Apr 29

Controversies· Aug 21

Macro· Apr 20

Technical Analysis· Dec 17

Regulars· Jul 29

Newcomers· Jan 29

Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround

Teva Enters Acceleration Phase of Transformation Supported by Multi-Year Launch Cycle, Oppenheimer Says

Viatris, Teva initiated at Outperform at Oppenheimer

Teva Eyes New Growth Phase After Securing Investment-Grade Ratings

Oppenheimer initiates Teva stock with outperform rating on pipeline

Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline

Also Discussed

Teva Pharmaceutical Industries Ltd. ADR

Company Information

Location

Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround

Teva Enters Acceleration Phase of Transformation Supported by Multi-Year Launch Cycle, Oppenheimer Says

Viatris, Teva initiated at Outperform at Oppenheimer

Teva Eyes New Growth Phase After Securing Investment-Grade Ratings

Oppenheimer initiates Teva stock with outperform rating on pipeline

Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline

Also Discussed

Social

Sep 2

Bullish· Apr 29

Bearish· May 7

Earnings· Nov 5

Analysts· Feb 12

Announcements· Apr 29

Controversies· Aug 21

Macro· Apr 20

Technical Analysis· Dec 17

Regulars· Jul 29

Newcomers· Jan 29